A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121)

Prasad Mathew; Robert Gerbing; Todd A. Alonzo; Tanya Wallas; Jerald Z. Gong; Rama Jasty; Dean T. Jorstad; Susana C. Raimondi; Cathy M. Chavez; Nancy L. Eisenberg; Betsy Hirsch; Alan Gamis; Franklin O. Smith; Robert J. Arceci

doi:10.1002/pbc.23164

A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121)

Prasad Mathew, Robert Gerbing, Todd A. Alonzo, Tanya Wallas, Jerald Z. Gong, Rama Jasty, Dean T. Jorstad, Susana C. Raimondi, Cathy M. Chavez, Nancy L. Eisenberg, Betsy Hirsch, Alan Gamis, Franklin O. Smith, Robert J. Arceci

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Based on its potential role in adult myelodysplastic syndrome (MDS), the Children's Oncology Group (COG) embarked on a phase II study using amifostine in pediatric MDS (WHO 2001 criteria) patients. Responses were evaluated after two cycles. Ten patients were enrolled; five were deemed ineligible, and four withdrew after the first course. Only one patient completed two courses, and was found to be in complete remission. The study was closed after being open for 2 years due to slow accrual. Studying a rare disease like MDS may pose insurmountable obstacles even in a large clinical trials group such as COG, in part because of the changing definitions of MDS and the rarity of adult type MDS in children. The role of amifostine in pediatric MDS was not known at the time of study.

Original language	English (US)
Pages (from-to)	1230-1232
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	57
Issue number	7
DOIs	https://doi.org/10.1002/pbc.23164
State	Published - Dec 15 2011

Keywords

Amifostine
Myelodysplastic syndrome
Pediatric
Phase II

Publisher link

10.1002/pbc.23164

Find It

Find It at U of M Libraries

Cite this

Mathew, P., Gerbing, R., Alonzo, T. A., Wallas, T., Gong, J. Z., Jasty, R., Jorstad, D. T., Raimondi, S. C., Chavez, C. M., Eisenberg, N. L., Hirsch, B., Gamis, A., Smith, F. O., & Arceci, R. J. (2011). A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121). Pediatric Blood and Cancer, 57(7), 1230-1232. https://doi.org/10.1002/pbc.23164

Mathew, P, Gerbing, R, Alonzo, TA, Wallas, T, Gong, JZ, Jasty, R, Jorstad, DT, Raimondi, SC, Chavez, CM, Eisenberg, NL, Hirsch, B, Gamis, A, Smith, FO & Arceci, RJ 2011, 'A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121)', Pediatric Blood and Cancer, vol. 57, no. 7, pp. 1230-1232. https://doi.org/10.1002/pbc.23164

@article{34dbcaf17e2d46a8b957a3d2738aff69,

title = "A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121)",

abstract = "Based on its potential role in adult myelodysplastic syndrome (MDS), the Children's Oncology Group (COG) embarked on a phase II study using amifostine in pediatric MDS (WHO 2001 criteria) patients. Responses were evaluated after two cycles. Ten patients were enrolled; five were deemed ineligible, and four withdrew after the first course. Only one patient completed two courses, and was found to be in complete remission. The study was closed after being open for 2 years due to slow accrual. Studying a rare disease like MDS may pose insurmountable obstacles even in a large clinical trials group such as COG, in part because of the changing definitions of MDS and the rarity of adult type MDS in children. The role of amifostine in pediatric MDS was not known at the time of study.",

keywords = "Amifostine, Myelodysplastic syndrome, Pediatric, Phase II",

author = "Prasad Mathew and Robert Gerbing and Alonzo, {Todd A.} and Tanya Wallas and Gong, {Jerald Z.} and Rama Jasty and Jorstad, {Dean T.} and Raimondi, {Susana C.} and Chavez, {Cathy M.} and Eisenberg, {Nancy L.} and Betsy Hirsch and Alan Gamis and Smith, {Franklin O.} and Arceci, {Robert J.}",

year = "2011",

month = dec,

day = "15",

doi = "10.1002/pbc.23164",

language = "English (US)",

volume = "57",

pages = "1230--1232",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - A phase II study of amifostine in children with myelodysplastic syndrome

T2 - A report from the Children's Oncology Group study (AAML0121)

AU - Mathew, Prasad

AU - Gerbing, Robert

AU - Alonzo, Todd A.

AU - Wallas, Tanya

AU - Gong, Jerald Z.

AU - Jasty, Rama

AU - Jorstad, Dean T.

AU - Raimondi, Susana C.

AU - Chavez, Cathy M.

AU - Eisenberg, Nancy L.

AU - Hirsch, Betsy

AU - Gamis, Alan

AU - Smith, Franklin O.

AU - Arceci, Robert J.

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Based on its potential role in adult myelodysplastic syndrome (MDS), the Children's Oncology Group (COG) embarked on a phase II study using amifostine in pediatric MDS (WHO 2001 criteria) patients. Responses were evaluated after two cycles. Ten patients were enrolled; five were deemed ineligible, and four withdrew after the first course. Only one patient completed two courses, and was found to be in complete remission. The study was closed after being open for 2 years due to slow accrual. Studying a rare disease like MDS may pose insurmountable obstacles even in a large clinical trials group such as COG, in part because of the changing definitions of MDS and the rarity of adult type MDS in children. The role of amifostine in pediatric MDS was not known at the time of study.

AB - Based on its potential role in adult myelodysplastic syndrome (MDS), the Children's Oncology Group (COG) embarked on a phase II study using amifostine in pediatric MDS (WHO 2001 criteria) patients. Responses were evaluated after two cycles. Ten patients were enrolled; five were deemed ineligible, and four withdrew after the first course. Only one patient completed two courses, and was found to be in complete remission. The study was closed after being open for 2 years due to slow accrual. Studying a rare disease like MDS may pose insurmountable obstacles even in a large clinical trials group such as COG, in part because of the changing definitions of MDS and the rarity of adult type MDS in children. The role of amifostine in pediatric MDS was not known at the time of study.

KW - Amifostine

KW - Myelodysplastic syndrome

KW - Pediatric

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=80053926040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053926040&partnerID=8YFLogxK

U2 - 10.1002/pbc.23164

DO - 10.1002/pbc.23164

M3 - Article

C2 - 21681928

AN - SCOPUS:80053926040

SN - 1545-5009

VL - 57

SP - 1230

EP - 1232

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

IS - 7

ER -

A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121)

Abstract

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this